BioSpace News Archive

Positive initial data from first Affimer-based rapid test strips for SARS-COV-2 spike protein

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced its corporate headquarters and manufacturing facility in Acton, MA, will be powered by solar-based, renewable energy beginning this week.

ProMIS Neurosciences, Inc. announces that the Board of Directors of the Corporation have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Corporation and its shareholders to adjourn the Corporation’s annual meeting of shareholders to 9:00 a.m. onJuly 29, 2020 and to change the location of the AGM to Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it received early notification from the U.S. Food and Drug Administration that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19.

Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s

Strategic Alliance Combines Yumanity’s Innovative Drug Discovery Platform with Merck’s Development and Commercialization Expertise in Neuroscience

Special Edition of Alkermes Inspiration Grants® Program Focused on Addressing Pandemic-Related Needs of People Living with Addiction, Serious Mental Illness, or Cancer

Antimicrobial resistance is a leading global health challenge i that requires urgent action to ensure a safer world for everyone, everywhere Effective surveillance and timely data feedback are critical for infection prevention and control programs, and informing appropriate use of anti-infectives New partnership in Ghana, Kenya, Malawi and Uganda will provide governments and public health community with critical decision-making inform

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan CEO and biopharma deal-maker, Brent Saunders; genomics pioneer and entrepreneur, Randy Scott, Ph.D.; and renowned economist and BridgeBio co-founder, Andrew Lo, Ph.D. “We are privileged to welcome these world-class company builders, inn

HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a phase 2 clinical trial of HST5040, an oral small molecule drug for the treatment of patients